A New Era for Pharmaceutical Trade & Compliance
On September 25, 2025, the U.S. government announced that branded and patented medicines imported into the country will face 100% tariffs unless manufacturers are actively building a U.S.-based plant. This unprecedented policy shift is set to reshape global pharma supply chains, compliance strategies, and investment decisions.
Who Is Impacted by 100% Drug Tariffs in the USA?
- Patented & branded drugs – generics are excluded for now
- Companies without U.S. manufacturing – strong pressure to establish or expand plants in the U.S.
- Biotechs and niche medicines – orphan drugs and lower-margin products may be hardest hit
Pharma Risks and Supply Chain Challenges from U.S. Drug Tariffs
Some important clarifications about the new tariff rules:
- Exemption tied to U.S. manufacturing investment – Companies “building” a U.S. plant may qualify for exemption.
- Applies only to branded, patented drugs – Generic medicines are excluded from the tariffs.
- Unclear scope of exemption – It remains uncertain whether the exemption covers all products of a company investing in the U.S. or only the drugs manufactured locally.
- Trade agreements and tariff caps – The EU cites agreements limiting tariffs on key goods (including pharmaceuticals) to 15%.
- Global reaction and uncertainty – The EU and Japan expect caps will shield their exporters, but questions remain about enforcement.
Pharma Risks and Supply Chain Challenges from U.S. Drug Tariffs
| AREA | IMPACT ON PHARMA | RISK/OPPORTUNITY |
|---|---|---|
| Trade & Market Access | Exports could become nonviable without U.S. investment | Companies may shift supply chains to the U.S. |
| Supply Chain Reorganisation | Need for U.S. manufacturing or local suppliers | Capital expenditure, new footprint strategies |
| Investment Pressure | Non-U.S. companies face pressure to build plants | Existing U.S. sites gain advantage |
| Regulatory & Legal Uncertainty | Tariff legality challenged; retaliation likely | Legal strategy and diplomacy essential |
| Biotech & Niche Drugs | Orphan/lower-margin drugs hardest hit | Risk to innovation and market launches |
| Contract Manufacturing (CMOs) | Grey area for U.S.-made under contract | Clarification on “manufactured in U.S.” needed |
How Pharmaceutical Companies Can Respond to U.S. Tariff Policy
To safeguard market access and reduce risk exposure, firms should act quickly:
- Map tariff exposure across product portfolios
- Explore U.S. manufacturing feasibility and site validation
- Strengthen supply chain resilience through dual sourcing and buffer strategies
- Ensure FDA compliance & inspection readiness for new or contracted U.S. facilities
- Develop trade risk scenarios and engage stakeholders proactively
Rephine’s Pharma Compliance and Supply Chain Support
Rephine is uniquely positioned to help pharmaceutical and biotech companies navigate this disruption:
✅ Tariff & Exposure Assessment – Identify products and supply lines at risk
✅ Manufacturing Footprint Strategy – Feasibility studies, validation, and supplier migration support
✅ Regulatory Compliance – FDA readiness and inspection-proof documentation
✅ Continuity Planning – Dual supply routes, risk mitigation, and resilience-building
✅ Stakeholder Engagement – Communication strategies with regulators and trade bodies
Prepare for 100% Drug Tariffs with Compliance and Risk Management
The new tariff landscape demands urgent action. Whether you’re a global pharma leader or an emerging biotech, Rephine helps you stay compliant, safeguard supply chains, and secure your market position in the U.S.
👉 Contact Rephine today to assess your exposure and build a strategy for resilience.
Dr. Eduard Cayón
CSO (Chief Scientific Officer)
About the Author:
Dr. Eduard Cayón is the Chief Scientific Officer (CSO) at Rephine, a global leader in GxP compliance and quality assurance.
We don’t just deliver audits or consultancy services — we partner with clients at every stage of their quality journey, offering end-to-end solutions that empower confidence and compliance.
With over 25 years of experience, Rephine has built an enviable reputation as the gold standard in the industry operating from four primary locations: Stevenage in the UK, Barcelona in Spain, India, and Shanghai in China.
Dr. Cayón, who holds a Ph.D. in Organic Chemistry, is a deeply experienced pharmaceutical industry consultant and auditor.
He is dedicated to supporting pharmaceutical, biotech, and medical device companies in meeting the highest standards of manufacturing and supply chain integrity.
